Treatment of Disseminated Cytomegalovirus (CMV) Infection

Initial Treatment Approach

The American Gastroenterological Association recommends intravenous ganciclovir (5 mg/kg twice daily) for 2-3 weeks as the first-line treatment for disseminated CMV infection, with potential transition to oral valganciclovir (900 mg twice daily) after 3-5 days if clinically improving 1, 2
For disseminated CMV causing systemic disease, prompt initiation of antiviral therapy is critical for optimal clinical response, as recommended by the Centers for Disease Control and Prevention 2, 3
Intravenous ganciclovir at 5 mg/kg twice daily for 2-3 weeks is the therapy of choice for disseminated CMV infections, according to the American College of Gastroenterology 1, 2
After 3-5 days of IV therapy, if clinical improvement is observed and oral absorption is adequate, transition to oral valganciclovir 900 mg twice daily for the remainder of the 2-3 week course may be considered, as suggested by the National Comprehensive Cancer Network 2, 4
For neurological CMV disease, combination therapy with ganciclovir and foscarnet might be preferred as initial therapy to maximize response, despite higher rates of adverse effects, as recommended by the Centers for Disease Control and Prevention 5, 6

In cases of ganciclovir resistance or intolerance, foscarnet for 2-3 weeks is the recommended alternative, according to the American College of Gastroenterology 1, 2
Cidofovir can be considered as a third-line agent, though it carries substantial risk of nephrotoxicity, as noted by the National Comprehensive Cancer Network 7
For CMV pneumonitis, adjunctive intravenous immunoglobulin (IVIG) can be administered, typically every other day for 3 to 5 doses, as suggested by the National Comprehensive Cancer Network 7

Weekly monitoring of CMV viral load by PCR is recommended to assess treatment response, as suggested by the European Society for Medical Oncology 8
Renal function should be closely monitored, especially with foscarnet or cidofovir therapy, as recommended by the Centers for Disease Control and Prevention 6

Treatment should continue for at least 2-3 weeks and until CMV is no longer detected in blood, as recommended by the American College of Gastroenterology 1, 7
In immunocompromised patients, discontinuation of immunosuppressive agents is associated with clinical improvement and decreased mortality, as noted by the American College of Gastroenterology 2
For HIV-infected patients with CMV disease, antiretroviral therapy (ART) should be initiated or optimized concurrently with CMV treatment, as recommended by the Centers for Disease Control and Prevention 6

Ganciclovir and valganciclovir can cause neutropenia, thrombocytopenia, anemia, nausea, diarrhea, and renal dysfunction, as noted by the Centers for Disease Control and Prevention 6
Foscarnet can cause nephrotoxicity, electrolyte abnormalities, and neurologic dysfunction, as reported by the Centers for Disease Control and Prevention 6
Cidofovir can cause substantial nephrotoxicity and potential ocular toxicity, as noted by the National Comprehensive Cancer Network 7